NCT07429643Not yet recruitingPhase 2/3
Endoscopic Ultrasound-Guided Loco-regional Chemotherapy Injection as Adjuvant Therapy for Locally Advanced Pancreatic Cancer.
Endoscopic Ultrasound-Guided Loco-regional Chemotherapy Injection as Adjuvant Therapy for Locally Advanced Pancreatic Cancer: A Randomized Controlled Trial.
Source: ClinicalTrials.gov · Last updated 24 Feb 2026
Brief summary (registry, in English)
this is a randomized controlled trial aims to compare between patients with locally advanced pancreatic cancer treated with EUS-guided injection of gemcitabine in addition to systemic chemotherapy, versus those who treated with the standard systemic chemotherapy alone, regarding to(progression -free survival and response rate). Researchers will compare Arm A: patients received EUS-FNI of gemcitabine plus standard systemic chemotherapy to Arm B : patients receiving the standard systemic chemotherapy alone.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 16 Feb 2026
- Start date
- 15 Apr 2026
- Primary completion date
- 15 Dec 2028
- Lead sponsor
- Assiut University
- Diseases
- Pancreatic cancer
- NCT number
- NCT07429643
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 20
- From 15 Apr 2026 to the primary completion date, 15 Dec 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Metastatic pancreatic cancer.
- prior pancreatic surgery or chemotherapy or radiotherapy. concurrent or prior malignancy. coexistent medical condition precluding protocol therapy.
Age
- Age \< 18 years old.
Who the study is looking for
- Age \> 18 years old.
- Patients recently diagnosed to have pancreatic adenocarcinoma based on histopathological examination.
- Locally advanced potentially resectable pancreatic cancer . .Eastern Cooperative Oncology Group performance status of 0 to 1. .Signed informed consent.
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.